The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Patient Power Founder Andrew Schorr caught with patient #1 in the elotuzumab trial, Jay Carty, to get his thoughts on the approval and his perspective on the future of myeloma treatment.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Advertisement